Business Description
Travere Therapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US89422G1076
Share Class Description:
TVTX: Ordinary SharesDescription
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.69 | |||||
| Equity-to-Asset | -0.06 | |||||
| Debt-to-Equity | -13.21 | |||||
| Debt-to-EBITDA | -1.27 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -3.66 | |||||
| Beneish M-Score | -2.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -22.3 | |||||
| 3-Year EBITDA Growth Rate | -12.9 | |||||
| 3-Year EPS without NRI Growth Rate | -44 | |||||
| 3-Year FCF Growth Rate | -8.3 | |||||
| 3-Year Book Growth Rate | -13 | |||||
| Future 3-5Y Total Revenue Growth Rate | 53.92 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.97 | |||||
| 9-Day RSI | 35.39 | |||||
| 14-Day RSI | 40.7 | |||||
| 6-1 Month Momentum % | 134.27 | |||||
| 12-1 Month Momentum % | 101.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.71 | |||||
| Quick Ratio | 1.68 | |||||
| Cash Ratio | 1.46 | |||||
| Days Inventory | 352.07 | |||||
| Days Sales Outstanding | 38.79 | |||||
| Days Payable | 989.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13 | |||||
| Shareholder Yield % | 0.19 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.21 | |||||
| Operating Margin % | -169.53 | |||||
| Net Margin % | -172.75 | |||||
| FCF Margin % | -181.58 | |||||
| ROE % | -325.82 | |||||
| ROA % | -52.6 | |||||
| ROIC % | -158.27 | |||||
| ROC (Joel Greenblatt) % | -1389.77 | |||||
| ROCE % | -66.47 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.51 | |||||
| EV-to-EBIT | -4.8 | |||||
| EV-to-EBITDA | -5.09 | |||||
| EV-to-Revenue | 7.96 | |||||
| EV-to-Forward-Revenue | 5.16 | |||||
| EV-to-FCF | -4.38 | |||||
| Price-to-Median-PS-Value | 1.06 | |||||
| Earnings Yield (Greenblatt) % | -20.83 | |||||
| FCF Yield % | -24.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TVTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Travere Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 203.447 | ||
| EPS (TTM) ($) | -4.55 | ||
| Beta | 0.77 | ||
| Volatility % | 79.14 | ||
| 14-Day RSI | 40.7 | ||
| 14-Day ATR ($) | 0.798166 | ||
| 20-Day SMA ($) | 18.2655 | ||
| 12-1 Month Momentum % | 101.43 | ||
| 52-Week Range ($) | 5.12 - 20.33 | ||
| Shares Outstanding (Mil) | 87.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Travere Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Travere Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Travere Therapeutics Inc Frequently Asked Questions
What is Travere Therapeutics Inc(TVTX)'s stock price today?
The current price of TVTX is $17.13. The 52 week high of TVTX is $20.33 and 52 week low is $5.12.
When is next earnings date of Travere Therapeutics Inc(TVTX)?
The next earnings date of Travere Therapeutics Inc(TVTX) is 2025-02-14 Est..
Does Travere Therapeutics Inc(TVTX) pay dividends? If so, how much?
Travere Therapeutics Inc(TVTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers